Compare AbbVie Inc (ABBV) vs eBay Inc (EBAY) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

EBAY trades at $111.98, up 1.67% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a net income margin of 18.57% and ROE of 47.38%, supported by revenue growth to $11.10B in 2025. Recent news highlights potential partnership talks with GameStop after a withdrawn $56B bid, adding volatility but strategic interest.

Outlook is positive with a consensus price target of $119.85, indicating ~7% upside, driven by earnings momentum and focus category growth. Risks include competitive pressures in e-commerce and market sensitivity to merger speculation. Investors may find value in sustained profitability and analyst buy ratings, though monitor execution on guidance.